Tebipenem (SPR994) Tissue Penetration in Diabetic Patients With Wound Infections and Healthy Volunteers Via In Vivo Microdialysis

Diabetes Clinical Trial

Official title:

Pharmacokinetics and Soft-Tissue Penetration of Tebipenem (SPR994) in Healthy Volunteer Subjects and Diabetic Patients With Lower Limb Infections

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04919954
• Other study ID #: HHC-2021-0109
• Status: Completed
• Phase: Phase 1
• Start date: July 1, 2021
• Est. completion date: December 23, 2022

Study information

• Verified date: October 2023
• Source: Hartford Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will determine the tissue penetration of a broad-spectrum orally bioavailable carbapenem, tebipenem pivoxil hydrobromide (SPR994) (Spero Therapeutics, Inc.), into the extracellular, interstitial fluid of soft tissue in diabetic patients with lower limb wound infections. Penetration will be compared with a group of healthy volunteer control participants.

Description:

This study will enroll 10 patients with diabetes who are admitted with a lower limb wound infection and 6 healthy volunteer control participants. The study will take place in an inpatient unit at Hartford Hospital for all patients and in the Clinical Research Center at Hartford Hospital for all healthy volunteers. All participants will receive 3 to 7 doses of tebipenem pivoxil hydrobromide (300 mg or 600 mg orally every 8 hours depending on renal function). A microdialysis probe (Mdialysis Inc., N. Chelmsford, MA) will be inserted into the subcutaneous soft tissue near the margin of the wound (patients) or in the thigh (healthy volunteers). The microdialysis probe is perfused with normal saline solution and samples are collected for the 8 hours following the final dose. A peripheral intravenous catheter will be inserted into an arm vein to collect blood samples simultaneously with microdialysis samples. Concentrations in tissue are compared with blood to determine percent penetration.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 12
• Est. completion date: December 23, 2022
• Est. primary completion date: August 30, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Exclusion Criteria - All patients/participants Participants in the diabetic wound group or healthy volunteer group will be excluded if any

of the following criteria are met:

1. Less than 18 years of age

2. History of hypersensitivity or allergy to tebipenem or its derivatives and any ß-lactam antibiotic

3. History of hypersensitivity to lidocaine or lidocaine derivatives

4. Concurrently receiving probenecid.

5. Males who are not surgically sterilized (with female partners of childbearing potential) and females of childbearing potential must agree to use two highly effective methods of contraception from screening, during this trial, and for 90 days after the last dose of study drug. A woman is considered of childbearing potential unless postmenopausal (=1 year without menses) or surgically sterilized via bilateral oophorectomy, hysterectomy, bilateral tubal ligation, or successful Essure® placement with a documented confirmation test at least 90 days after the procedure. Highly effective contraception is defined as a method of contraception that has a less than

1% failure rate when used consistently and correctly. These methods are as follows:

• Hormonal contraceptives (eg, combined oral contraceptives, patch, vaginal ring, injectables, and implants).
• Intrauterine device or intrauterine system.
• Double-barrier methods of contraception (eg, male condom with diaphragm or male condom with cervical cap).
• Monogamous relationship with a vasectomized partner.
• Total abstinence, in accordance with the lifestyle of the subject.

6. Any other documented reason felt by the investigator to potentially affect the outcomes of the study Additional Exclusion Criteria for Diabetic Patient Study Group

1. Participants likely to require multiple surgical interventions during the study period, which could affect placement of the microdialysis catheter

2. Creatinine clearance (CrCl) < 30ml/min, as calculated by Cockroft-Gault using ideal body weight Additional Exclusion Criteria for Healthy Volunteer Control Group

1. Body Mass Index (BMI) = 35 kg/m2

2. Creatinine clearance (CrCl) < 50ml/min, as calculated by Cockroft-Gault using ideal body weight

3. Presence of anemia, thrombocytopenia, or leukopenia as defined by hematocrit, platelet, or white blood cell count < 75% of the lower limit of normal

4. Aspartate transaminase, alanine aminotransferase, or alkaline phosphatase greater than five times upper limit of normal

5. Total bilirubin greater than three times the upper limit of normal

6. Any known active co-morbidity listed on medical history or that becomes apparent during physical examination

7. Positive urine drug screen (cocaine, THC, opiates, benzodiazepines, and amphetamines)

8. History of regular alcohol consumption exceeding 7 drinks/week for females or 14 drinks/week for men (1 drink = 5 ounces of wine or 12 ounces of beer or 1.5 ounces of hard liquor) within 6 months of screening.

9. Use of tobacco- or nicotine-containing products in excess of the equivalence of 5 cigarettes per day.

10. Consumption of caffeine between Study Days -1 and 2.

11. Use of prescription or non-prescription drugs, vitamins, or dietary supplements within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study medication, with the exception of acetaminophen at doses of = 1 g/day. The use of hormonal methods of contraception (including oral and transdermal contraceptives, injectable progesterone, progestin subdermal implants, progesterone-releasing IUDs, postcoital contraceptive methods) are permitted.

Related Conditions & MeSH terms

• ABSSSI
• Communicable Diseases
• Diabetes
• Healthy Volunteers
• Infections
• Wound Infection

Intervention

Drug:
• Tebipenem Pivoxil Hydrobromide
Tebipenem 300 mg or 600 mg will be administered orally every 8 hours for total of 3 to 7 doses

Locations

Country	Name	City	State
United States	Hartford Hospital	Hartford	Connecticut

Sponsors (2)

Lead Sponsor	Collaborator
Hartford Hospital	Spero Therapeutics

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Tebipenem Pivoxil Hydrobromide Tissue Penetration	The ratio of tebipenem tissue concentrations to blood concentrations following the final tebipenem dose	8 hours
Secondary	Tebipenem Pivoxil Hydrobromide Area Under the Curve (AUC) in Tissue	The area under the drug concentration-time curve (AUC) in tissue reflects the actual tissue exposure to drug after administration of a dose of the drug and is expressed in mg*h/L. Venous blood will be obtained via peripheral intravenous catheter immediately before administration of the last dose (pre-dose timepoint), and at 9 time-points post-dose. Dialysate samples of 120µL will be collected in 200µL microvials simultaneously with plasma samples.	8 hours